Skip to main content
CRBP
NASDAQ Life Sciences

Corbus Pharmaceuticals 公布第四季度每股亏损 $1.25

feedReported by Dow Jones Newswires
Sentiment info
Negative
Importance info
7
Price
$8.01
Mkt Cap
$140.6M
52W Low
$4.64
52W High
$20.56
Market data snapshot near publication time

summarizeSummary

Corbus Pharmaceuticals 公布第四季度每股亏损 $1.25。这一财务更新是在公司最近公布其肥胖药物 CRB-913 阶段 1a 临床试验积极数据之后，于 2 月 25 日公布的。对于一家临床阶段生物技术公司，季度亏损是衡量财务健康和运营支出率的关键指标，影响投资者对未来资本需求的看法。交易者将在公司的现金状况和开发时间表的背景下评估这一亏损，特别是考虑到其相对较小的市值。

在该公告发布时，CRBP的交易价格为$8.01，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.4亿。 52周交易区间为$4.64至$20.56。 这则新闻被评估为消极市场情绪，重要性评分为7/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed CRBP - Latest Insights

CRBP
Apr 16, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Corbus Pharmaceuticals Updates CEO & CFO Employment Agreements with Enhanced Severance
Sentiment: Neutral
View Wiseek Article
CRBP
Apr 14, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Corbus Pharmaceuticals Completes Enrollment for Phase 1b Obesity Trial (CRB-913), Data Expected Summer 2026
Sentiment: Positive
View Wiseek Article
CRBP
Apr 07, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Corbus Pharmaceuticals Secures FDA Alignment for CRB-701 Registrational Path in HNSCC and Cervical Cancer
Sentiment: Positive
View Wiseek Article
CRBP
Apr 07, 2026, 8:05 AM EDT
Source: Reuters
Importance Score:
8
FDA Aligns with Corbus on CRB-701 Registration Path for Two Cancer Indications
Sentiment: Positive
View Wiseek Article
CRBP
Apr 02, 2026, 4:49 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Shareholders to Vote on Significant Equity Plan Expansion, Potentially Diluting Shares by 17%
Sentiment: Negative
View Wiseek Article
CRBP
Mar 11, 2026, 5:06 PM EDT
Filing Type: S-3
Importance Score:
8
Corbus Pharmaceuticals Registers $300M Universal Shelf for Future Capital Raises, Signaling Substantial Potential Dilution
Sentiment: Negative
View Wiseek Article
CRBP
Mar 09, 2026, 4:16 PM EDT
Filing Type: 10-K
Importance Score:
8
Corbus Pharma Secures $70.2M Funding at Premium, Advances Oncology & Obesity Programs
Sentiment: Positive
View Wiseek Article
CRBP
Mar 09, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
8
CRB-701 Receives FDA Fast Track Designation for Head and Neck, Cervical Cancers
Sentiment: Positive
View Wiseek Article
CRBP
Mar 09, 2026, 7:43 AM EDT
Filing Type: 8-K
Importance Score:
8
Corbus Pharmaceuticals Secures Funding into 2028, Reports Q4 Loss, and Updates Positive Clinical Data
Sentiment: Neutral
View Wiseek Article
CRBP
Mar 09, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Corbus Pharmaceuticals Reports $1.25 Per Share Loss in Q4
Sentiment: Negative
View Wiseek Article